DoW Amyotrophic Lateral Sclerosis Research Program, Therapeutic Idea Award
Funding Opportunity Number: HT942526ALSRPTIA
About the Opportunity
The fiscal year 2026 (FY26) Amyotrophic Lateral Sclerosis Research Program (ALSRP) Therapeutic Idea Award (TIA) supports new, innovative, high-risk, high-gain ideas aimed at amyotrophic lateral sclerosis (ALS) drug or therapy discovery. The studies supported by this award mechanism are expected to be hypothesis-driven and generate preliminary data for future avenues of therapeutic investigation.
Potential impact and innovation are important features of the TIA. Applications may demonstrate the ability to achieve interpretable results in the absence of preliminary data supporting the hypothesis. While the inclusion of preliminary data is not prohibited, the strength of the application should rely on the approach.
Funding Details
- Expected Number of Awards: 12
- Estimated Total Program Funding: $10,080,000
- Cost Sharing or Matching Requirement: No
Eligibility
Eligible Applicants: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility".
Key Dates
- Posted Date: May 04, 2026
- Last Updated Date: May 04, 2026
- Closing Date for Applications: Sep 30, 2026
- Archive Date: Oct 30, 2026
Contact Information
If you have difficulty accessing the full announcement electronically, please contact:
- eBRAP Help Desk Phone: 301-682-5507
- Email: help@eBRAP.org